BACKGROUND: Current lymph node (LN) staging for salivary gland cancer (SGC) is extrapolated from mucosal head and neck squamous cell carcinoma. However, given its unique biology and clinical behavior, it is possible that a SGC-specific LN staging system would be more accurate. METHODS: Patients from the National Cancer Data Base with nonmetastatic SGC of the head and neck who were diagnosed from 2004 through 2013 and underwent surgical resection and neck dissection removing at least 10 LNs were included. Multivariable models were constructed to assess the association between survival and LN factors, including number of metastatic LNs, extranodal extension, LN size, and lower LN involvement. RESULTS: Overall, 4520 patients met the inclusion criteria. An increasing number of metastatic LNs was found to be strongly associated with worse survival without plateau. The risk of death increased more rapidly up to 4 LNs (hazard ratio, 1.34; 95% confidence interval, 1.27-1.41 [P <.001]), and was more gradual for additional LNs >4 (hazard ratio, 1.02; 95% confidence interval, 1.01-1.03 [P <.001]). LN size, extranodal extension, and lower LN involvement appeared to have no impact on survival when accounting for the number of metastatic LNs. Recursive partitioning analysis was used to create a novel SGC LN staging system in which N0 indicates 0 positive LNs, N1 indicates 1 to 2 positive LNs, N2 indicates 3 to 21 positive LNs, and N3 indicates 22 positive LNs. This system exhibited greater concordance than the current American Joint Committee on Cancer (eighth edition) system. CONCLUSIONS: Quantitative LN burden is an important determinant of survival in patients with SGC. Use of this variable may improve SGC staging. Cancer
INTRODUCTION
Salivary gland cancers (SGCs) are a rare, heterogeneous collection of malignancies arising from the major or minor salivary glands in the head and neck that are primarily managed surgically. In addition to grade and tumor stage, one of the primary factors associated with disease recurrence and survival in patients with SGC is the presence of lymph node (LN) metastases, [1] [2] [3] [4] which may vary in frequency according to the site of the primary tumor. 1, 2, 5, 6 Current LN staging systems for SGC are extrapolated from mucosal head and neck squamous cell carcinoma. 7 However, given that SGC has distinct biology, clinical behavior, and treatment paradigms in comparison with head and neck squamous cell carcinoma, it is possible that LN staging that is specific for patients with salivary malignancies could outperform current methodology.
The number of cervical LNs containing metastases is emerging as a powerful predictor of outcome in patients with head and neck cancer. [8] [9] [10] [11] In patients with oral cavity cancers, 8 laryngeal cancers, 11 and hypopharyngeal cancers, 11 the number of pathologically positive LNs (LN1) has been shown to strongly correlate with survival, representing a better metric of prognosis than classic LN factors included in the American Joint Committee on Cancer (AJCC) eighth edition staging system such as LN size, laterality, and extranodal extension (ENE). In addition, the AJCC eighth edition pathologic nodal staging system for patients with p16-positive oropharyngeal cancer is now entirely based on the number of pathologic LNs. However, to the best of our knowledge, less is known regarding the impact of quantitative LN burden in patients with SGC.
With this background, we sought to define a novel LN staging system for SGC using data from patients with SGC undergoing surgical resection and neck dissection in the National Cancer Data Base (NCDB). We hypothesized that, similar to other head and neck cancers, quantitative LN metastatic burden is a central factor for predicting survival outcomes in patients with SGC. Moreover, we assessed the comparative impact of a variety of other LN factors, including size, ENE, and lower LN involvement.
MATERIALS AND METHODS

Data Source
The NCDB is a hospital-based registry representing approximately 70% of all newly diagnosed cancer cases in the United States. It comprises data from >1500 American College of Surgeons Commission on Cancer (CoC)-accredited cancer programs. 12 The NCDB is a registry maintained by the CoC of the American College of Surgeons and the American Cancer Society. There are established criteria with which to certify the quality of the submitted data, as well as an application process to obtain the data. However, upon distribution of the data, the CoC of the American College of Surgeons and the American Cancer Society are not responsible for the analysis and conclusions presented in this article. All data in the current study were abstracted from the NCDB, deidentified, and investigated. This study was deemed exempt from review by the Cedars-Sinai Medical Center institutional review board.
Histologies
The histologies included in the current study were based on the 2 most recent World Health Organization SGC classification systems. 13, 14 Included International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) histology codes were 8012, 8022, 8041, 8047, 8200, 8201,  8255, 8260, 8290, 8310, 8410, 8430, 8440, 8480, 8481,  8500, 8525, 8550, 8562, 8571, 8574, 8940, 8941, and  8980 . We excluded all squamous cell carcinomas even if they involved the major salivary glands, given that these commonly represent LN metastases from cutaneous head and neck sites.
Patients
All adult patients aged 18 years who were diagnosed between 2004 and 2013 from the NCDB with invasive cancers of salivary histology arising from either the major salivary glands or other head and neck subsites who underwent surgical resection and neck dissection as their primary treatment modality were included (34,959 patients). The Consolidated Standards of Reporting Trials (CONSORT) describes the patients included in this analysis (see Supporting Fig. 1 ). Exclusion criteria included patients with noninvasive histology (63 patients), patients with distant metastases at the time of presentation (1850 patients), patients with unknown follow-up details (3536 patients), patients with no surgery to the primary site (186 patients), patients who were missing pathological T classification (397 patients) or pathological N classification (12,364 patients) information, those who received any oncological therapy before surgery (841 patients), and patients for whom there was an unclear sequence of treatment (265 patients). Patients with adenosquamous histology (163 patients) were excluded because this represents a malignancy of the surface epithelium and not of the salivary glands. 14 To exclude biopsies or incidentally removed LNs in the primary specimen, patients with neck dissections yielding <10 LNs were excluded (10,354 patients). We also excluded patients without data regarding LN count (420 patients). This left 4520 patients, who formed the study cohort. The top quintile of patients in terms of the number of cases treated at their treating facility were defined as receiving treatment at high-volume facilities, and all other patients were considered to have received treatment at lower volume facilities.
Statistical Analysis
Missing data patterns among grade, ENE, LN size, surgical margins, and LN involvement were assessed by the method proposed by Little, and were deemed not missing completely at random. 15 Missing rates among the variables were 26.8% for grade, 26.5% for ENE, 13.7% for LN size, 5.7% for surgical margins, and 5.1% for LN involvement. Missing data were imputed using multiple imputation using fully conditional specifications implemented by the multiple imputation by chained equations (MICE) algorithm as described by Van Buuren and the predictive mean matching method as described by Rubin. 16, 17 The primary outcome was overall survival (OS), as assessed from time of diagnosis to the date of death or last follow-up. Baseline characteristics were compared with the Wilcoxon-Mann-Whitney test and 2-sample Student t tests for continuous variables and with the chisquare test for categorical covariates. The median followup was calculated with the reverse Kaplan-Meier method. Estimated survival functions were generated via the Kaplan-Meier method and compared with the logrank test. 18 Univariate and multivariable survival analyses were performed with the Cox proportional hazards model. 19 Variable selection was performed with backwards selection, optimizing for Akaike information criterion. The proportional hazards assumption was assessed using Schoenfeld residuals. 20 The number of positive LNs and number of LNs examined were analyzed as continuous variables and modeled nonlinearly with respect to OS using restricted cubic splines. The optimal number of knots was selected based on the Akaike information criterion. Knot locations were placed in default quantiles as described by Harrell. 21 For the number of positive LNs, 4 knots were placed at the 5th, 35th, 65th, and 95th percentiles, respectively, corresponding to 1, 2, 6, and 37 LN1. For the number of LNs examined, 3 knots were placed at the 10th, 50th, and 90th percentiles, respectively, corresponding to 11, 26, and 52 LN1. Change points were identified by fitting a piecewise linear regression model on the log relative hazard of the number of LN 1 and the number of LNs examined. 22, 23 Recursive partitioning analysis (RPA) with a conditional inference tree was used to develop a novel LN staging system. The conditional inference tree was created using independent LN predictors of mortality, and estimated by binary recursive partitioning in a conditional inference framework developed by Hothorn et al, Hothorn and Zeileis, and Strasser and Weber. [24] [25] [26] Performance of the RPA-derived LN staging system was compared with the AJCC eighth edition staging system using c-indices in patients with determinable AJCC stage. Internal validation was performed using bootstrapping with 1000 replicates to correct for possible optimism in c-indices.
Cancer
All statistical analyses were performed with R (version 3.4.0; R Foundation, Vienna, Austria) with 2-sided tests and a significance level of .05.
RESULTS
Patient Cohort
Overall, 4520 patients met the inclusion criteria, including 2196 patients with LN-positive disease and 2324 patients with LN-negative disease (see Supporting Table 1 ). The median follow-up was 54.3 months. The mean number of LNs examined was 28.1 ( 6 the standard deviation [SD] of 16.3), and the mean number of metastatic LN identified was 4.2 (6SD of 10.2). In total, 78.9% (1733 patients) and 57.5% (1337 patients), respectively, of patients with LN-positive and LN-negative disease underwent adjuvant radiotherapy(P < .001). Similarly, 30.4% (667 patients) of patients with LN-positive disease and 5.3% (123 patients) of patients with LN-negative disease received adjuvant chemotherapy (P < .001). The percentage of patients with positive LNs varied substantially by histology, with positive LNs found in approximately 75% of salivary duct carcinoma, 65% of adenocarcinoma, 55% of other carcinomas (including carcinoma ex pleomorphic adenoma), 41% of mucoepidemoid carcinoma, 34% of adenoid cystic carcinoma, and 26% of acinic cell carcinoma neck dissection specimens, respectively.
Number of Metastatic LN
In univariate analysis, an increasing number of metastatic LNs was found to be strongly predictive of worse OS (P < .001) ( Table 1 ). The estimated 5-year OS rates were 81.7%, 60.6%, 36.9%, 30.1%, and 13.9%, respectively, for patients with 0, 1 to 2, 3 to 9, 10 to 19, and 20 metastatic LNs (see Supporting Fig. 2A) . A similar impact for the number of metastatic LNs was seen in the patients in the N2b subgroup (see Supporting Fig. 2B ). After adjusting for other clinical and demographic factors using multivariable Cox regression (Table 1) , the number of metastatic LNs remained strongly associated with OS (P < .001). Using a 4-knot restricted cubic spline function, the mortality risk escalated continuously with the increasing number of metastatic LNs without plateau (Fig. 1) . Given the nonlinear relationship between mortality and the number of metastatic LNs, a change point at 4 metastatic LNs was identified. Table 2) .
Number of LNs Examined
An increasing number of LNs examined was found to be associated with improved OS in multivariable analyses (P 5 .007 Table 2) .
Metastatic LN Features
After adjustment for covariates, ENE, lower neck (level 4-5), contralateral LN involvement (N2c), and LN size were found to have no significant impact on survival (Table 1) .
Proposed LN Staging System
RPA based on the number of metastatic LNs generated a novel LN staging schema (Fig. 2) 
Histologic Subgroup Analysis
Because SGC is a heterogeneous disease comprised of various histologies of different biologic and clinical behavior, we performed an analysis of the risk of mortality as a nonlinear function of the number of LN1, using a 4-knot restricted cubic spline function, for each of the 6 main histologic groups in this study (see Supporting Fig. 3 ) (see Supporting Table 3 ). Although there were some differences in the slope of these functions, including a stronger risk of death per LN at lower LN numbers for less lymphotropic histologies such as adenoid cystic carcinoma and acinic cell carcinoma, an increasing number of positive LNs generally was associated with a continuously increasing risk of death for all histologic subtypes. We found that our proposed LN staging system produced excellent separation of survival curves across histologies (see Supporting Fig. 4) , although there were relatively few patients with acinic cell carcinoma or adenoid cystic carcinoma classified as N3 in our system.
Proposed Composite Stage Grouping
Pathologic AJCC T classification and our proposed LN classification both were found to be strongly and independently associated with mortality in the current study (see Supporting Table 2 ). Therefore, we designed a novel proposed composite stage grouping, analogous to the AJCC prognostic stage groups, by grouping patients based on the sum of their AJCC T classification and proposed LN classification (stage I: T1N0; stage II: T2N0/T1N1; stage  IIIA: T3N0/T2N1/T1N2; stage IIIB: T3N1/T4N0/  T2N2/T1N3; stage IIIC: T4N1/T3N2/T2N3; stage  IVA: T4N2/T3N3; and stage IVB: T4N3) . This produced 7 relatively similarly sized stage groups with clearly distinct survival curves and incrementally increased mortality (Fig. 4) . The 5-year OS rate was 92.1%, 85.1%, 68.4%, 56.5%, 37.3%, 25.6%, and 5.3%, respectively, for proposed stages I through IVB.
DISCUSSION
In the current study, we demonstrated that the absolute number of positive cervical LNs is a critical predictor of SGC mortality. Each additional metastatic LN increased the risk of death without plateau. The impact was greatest up to 4 positive LNs, with each positive LN conferring an added 34% increased risk of death, whereas each positive LN beyond this increased the relative mortality by 2% (Table 2 ). Other LN features including size, contralaterality, ENE, and lower neck involvement were found to have no impact on survival. The centrality of quantitative metastatic LN burden in determining survival in patients with SGC is consistent with its importance in other head and neck cancers, 8, 11 and suggests that this variable should play a more prominent role in staging and, potentially, adjuvant treatment recommendations.
Using RPA, we designed a novel SGC-specific LN staging system based on the number of positive LN. The RPA-derived staging system exhibited greater concordance than the AJCC eighth edition system, although the magnitude of difference was relatively small. Nevertheless, the proposed LN classification system has numerous advantages over the AJCC system. It is designed specifically for SGC, rather than extrapolated from head and neck squamous cell carcinoma, a biologically and clinically distinct entity. Thus, the proposed staging system ignores ENE, which is a strong prognostic factor in head and neck squamous cell carcinoma included in the AJCC eighth edition SGC staging system that was found to have no independent impact on survival among patients with SGC in our study. In addition, our proposed system is relatively simple, given that it is based on a single variable and contains only 3 distinct categories for patients with LN 1 disease: 1) N1 indicates 1 to 2 LN1; 2) N2 indicates 3 to 21 LN1; and 3) N3 indicates 22 LN1. The proposed staging system also has a relatively even distribution of patients across disease stages, whereas certain AJCC eighth edition stages such as N2c and N3a are very uncommon in SGC. Last, the proposed staging system identifies patients with 22 LNs as an "ultra-high risk" group of patients with >6 times the risk of mortality as LN-negative patients, which is nearly double the risk of any LN classification group identified by the AJCC system. Given these advantages, it is possible that the proposed LN staging system will not only improve prognostication but will more accurately identify patients who would benefit from adjuvant therapy or clinical trial enrollment.
The results of the current study also support the importance of thorough neck dissection in a subset of patients with SGC. Metastatic LNs portend a negative prognosis in terms of disease recurrence and long-term survival. 27 Thus, therapeutic neck dissection remains an integral part of the management protocol to extirpate possible micrometastatic disease and occult metastases in SGC patients at high risk of regional spread or with gross nodal metastases. 3, 28, 29 We found that each additional LN harvested above 10 LNs improved relative survival by 1.2% until plateauing beyond 33 LNs (Table 2) . Although this has a much smaller impact on survival than the number of metastatic LNs, its importance stems from the fact that it largely can be controlled by the physician. The benefit of increased LN yield is likely the result of multiple factors. This may in part be a function of the therapeutic effect of removing all deposits of microscopic disease. In addition, given that the number of metastatic LNs can affect the decision regarding adjuvant radiation, it is possible that higher LN yields allow for more accurate triaging of patients to adjuvant therapy. However, the number of LNs harvested also is likely a surrogate of quality, both for surgeons and pathologists. It is widely recognized that clinical volume and subspecialty expertise are important drivers of outcome in patients with head and neck cancer. 30, 31 It is important to note that these results suggest only that in patients with SGC who require neck dissection due to clinically suspicious lymph nodes or high risk features, a more thorough dissection is better than less thorough dissection. Our results do not support neck dissection in unselected patients with SGC. All patients in the current study had at least 10 LNs dissected, and therefore unquestionably represent a relatively highrisk subset of patients with SGC, including a substantial percentage who had clinically positive LNs.
The current study has multiple limitations. Most significantly, this is a retrospective observational study. Selection bias may have influenced the administration of adjuvant therapies such as radiotherapy, chemotherapy, and hormonal therapy, as well as the type of resection and neck dissection performed. As noted above, we required all patients to have at least 10 LNs dissected, and therefore the results presented herein may not be applicable to patients with low-risk SGC, for whom neck dissection in not required. In addition, SGC is inherently heterogeneous, comprising numerous different histologies. Although we found that our LN classification system was fairly accurate in each histologic subtype, it is possible that histology-specific SGC staging would outperform our system if sufficient patient numbers were available to develop it. It also should be noted that classifying SGC can be challenging, especially at lower-volume centers without subspecialized pathologists. Thus, it is likely that there is variability in both histological classification and grading across the approximately 1500 facilities contributing data to the NCDB in comparison with what would be observed with a central pathologic review. The NCDB also does not capture certain prognostic factors, such as perineural invasion, that could influence patterns of care and survival. Moreover, several important variables were not available for all patients, including tumor grade, ENE, and surgical margins. We used multiple imputation to account for this, but any methodology to account for missing data has limitations and the potential for bias. Last, the NCDB has no information regarding patterns of disease recurrence, and therefore it is not clear whether the increased mortality risk conveyed by increasing numbers of pathologic LNs is a result of regional disease recurrence, distant disease recurrence, or both. This would be an interesting topic for investigation in other large data sets of salivary cancer cases. Despite these limitations, we believe the central findings of the current study, among them that the number of positive LNs is strongly associated with survival and can improve LN staging in patients with SGC, are robust.
Conclusions
Quantitative metastatic LN burden is strongly associated with mortality in patients with SGC, with each additional metastatic LN conferring an increased risk of death without plateau. Staging parameters currently in use, including LN size, contralaterality, and ENE, lack independent prognostic value when accounting for the number of metastatic LNs. This information ultimately will help triage high-risk patients who may benefit from more aggressive adjuvant therapy.
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